1
|
Nawata T, Honda T, Sakai H, Tsuji S, Otsuka M, Uchinoumi H, Kobayashi S, Yamamoto T, Asagiri M, Yano M. Dantrolene, a ryanodine receptor stabilizer, is a candidate immunomodulator for treating rheumatic disease. Scand J Rheumatol 2024; 53:217-219. [PMID: 38293969 DOI: 10.1080/03009742.2023.2297519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2023] [Accepted: 12/18/2023] [Indexed: 02/01/2024]
Affiliation(s)
- T Nawata
- Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Japan
| | - T Honda
- Department of Pharmacology, Yamaguchi University Graduate School of Medicine, Ube, Japan
| | - H Sakai
- Department of Pharmacology, Yamaguchi University Graduate School of Medicine, Ube, Japan
| | - S Tsuji
- Department of Pharmacology, Yamaguchi University Graduate School of Medicine, Ube, Japan
| | - M Otsuka
- Department of Pharmacology, Yamaguchi University Graduate School of Medicine, Ube, Japan
| | - H Uchinoumi
- Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Japan
| | - S Kobayashi
- Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Japan
| | - T Yamamoto
- Faculty of Health Sciences, Yamaguchi University Graduate School of Medicine, Ube, Japan
| | - M Asagiri
- Department of Pharmacology, Yamaguchi University Graduate School of Medicine, Ube, Japan
| | - M Yano
- Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Japan
| |
Collapse
|
2
|
Baba Y, Hida N, Sambe T, Abe M, Kabasawa N, Sakai H, Yoshimura K, Fukuda T. Efficacy of Venetoclax and Azacitidine in Acute Myeloid Leukemia Compared to Azacitidine Monotherapy: Real-World Experience. Anticancer Res 2024; 44:2003-2007. [PMID: 38677735 DOI: 10.21873/anticanres.17003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2024] [Revised: 02/24/2024] [Accepted: 03/04/2024] [Indexed: 04/29/2024]
Abstract
BACKGROUND/AIM The combination of venetoclax (VEN) and azacitidine (AZA) (VEN+AZA) leads to higher complete remission rates and longer overall survival (OS) in patients with untreated acute myeloid leukemia (AML) who are ineligible for intensive combination chemotherapy. In practice, the doses of VEN and AZA are reduced at the attending physician's discretion to avoid adverse events; however, the impact of dose and duration reductions has not been fully clarified. We analyzed whether the efficacy was maintained with reduced VEN+AZA compared to AZA monotherapy in the real world. PATIENTS AND METHODS A total of 33 patients were included; 17 (10 newly diagnosed, 7 primary refractory or relapsed) received VEN+AZA, and 16 (7 newly diagnosed, 9 primary refractory or relapsed) received AZA. We analyzed complete remission (CR) and CR with incomplete hematologic recovery (CRi) rates, OS, and the incidence of adverse events. RESULTS CR/CRi were achieved in 7/17 (41.2%) and 11/17 (64.7%) patients in the VEN+AZA group and 0/15 (0%) and 2/15 (6.7%) patients in the AZA group, respectively. The CR/CRi rate was higher in the VEN+AZA group than in the AZA group (p=0.001). OS was longer in the VEN+AZA group than in the AZA group (p=0.03), with a median of 506 days [95% confidence interval (CI)=234-585 days] and 208 days (95% CI=52-343 days), respectively. CONCLUSION The doses of the VEN+AZA combination were reduced at the attending physician's discretion, resulting in a higher CR/CRi rate and longer OS than AZA monotherapy and is considered useful for AML in the real world.
Collapse
Affiliation(s)
- Yuta Baba
- Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Kanagawa, Japan;
- Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan
| | - Noriko Hida
- Department of Clinical Research and Development, Graduate School of Pharmacy, Showa University, Tokyo, Japan
| | - Takehiko Sambe
- Department of Pharmacology, Graduate School of Medicine, Showa University, Tokyo, Japan
| | - Maasa Abe
- Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Kanagawa, Japan
| | - Nobuyuki Kabasawa
- Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Kanagawa, Japan
| | - Hirotaka Sakai
- Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Kanagawa, Japan
| | - Kiyoshi Yoshimura
- Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan
| | - Tetsuya Fukuda
- Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Kanagawa, Japan
| |
Collapse
|
3
|
Watanabe S, Yoshioka H, Sakai H, Hotta K, Takenoyama M, Yamada K, Sugawara S, Takiguchi Y, Hosomi Y, Tomii K, Niho S, Nishio M, Kato T, Takahashi T, Ebi H, Aono M, Yamamoto N, Ohe Y, Nakagawa K. Association between skin toxicity and efficacy of necitumumab in squamous non-small-cell lung cancer: a pooled analysis of two randomized clinical trials-SQUIRE and JFCM. ESMO Open 2024; 9:102975. [PMID: 38520847 PMCID: PMC10980953 DOI: 10.1016/j.esmoop.2024.102975] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2023] [Revised: 12/14/2023] [Accepted: 02/29/2024] [Indexed: 03/25/2024] Open
Abstract
BACKGROUND Efficacy of necitumumab [recombinant human monoclonal antibody that blocks the ligand binding epidermal growth factor receptor (EGFR)] in patients with squamous (SQ) non-small-cell lung cancer (NSCLC) has been confirmed in two randomized clinical trials (SQUIRE and JFCM). This study evaluated the association between efficacy and initial skin toxicity with necitumumab treatment by analyzing pooled data from two clinical trials (SQUIRE and JFCM). MATERIALS AND METHODS Data of 635 patients with SQ-NSCLC (intent-to-treat population) treated with necitumumab plus gemcitabine and cisplatin (N + GC) were pooled from two clinical trials (SQUIRE and JFCM). The relationship between skin toxicities developed by the end of the second cycle and efficacy was evaluated. Efficacy endpoints included overall survival (OS), progression-free survival (PFS), and objective response rate (ORR). Univariate and multivariate analyses were carried out for these endpoints. RESULTS OS and ORR were associated with skin toxicity, whereas PFS was not. Patients with grade ≥2 or grade 1 skin toxicity had significantly longer OS compared to patients without skin toxicity (grade 0) in the N + GC group [median = 15.0 (grade ≥2); 12.7 (grade 1); 9.4 (grade 0) months; hazard ratio (HR) = 0.51 (grade ≥2 to grade 0); 95% confidence interval (CI) 0.40-0.64, P < 0.001 and HR = 0.64 (grade 1 to grade 0); 95% CI 0.52-0.80, P < 0.001]. In multivariate analysis, OS was significantly associated with skin toxicity. CONCLUSIONS A significant association was found between necitumumab-induced skin toxicity and efficacy. These results are consistent with the previously reported association between other EGFR inhibitors-induced skin toxicity and efficacy.
Collapse
MESH Headings
- Humans
- Carcinoma, Non-Small-Cell Lung/drug therapy
- Carcinoma, Non-Small-Cell Lung/pathology
- Lung Neoplasms/drug therapy
- Lung Neoplasms/pathology
- Male
- Female
- Middle Aged
- Aged
- Antibodies, Monoclonal, Humanized/therapeutic use
- Antibodies, Monoclonal, Humanized/pharmacology
- Antibodies, Monoclonal, Humanized/adverse effects
- Randomized Controlled Trials as Topic
- Adult
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Antineoplastic Combined Chemotherapy Protocols/pharmacology
- Antineoplastic Combined Chemotherapy Protocols/adverse effects
- Gemcitabine
- Carcinoma, Squamous Cell/drug therapy
- Carcinoma, Squamous Cell/pathology
- Deoxycytidine/analogs & derivatives
- Deoxycytidine/therapeutic use
- Cisplatin/therapeutic use
- Cisplatin/pharmacology
- Cisplatin/adverse effects
- Aged, 80 and over
Collapse
Affiliation(s)
- S Watanabe
- Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata
| | - H Yoshioka
- Department of Thoracic Oncology, Kansai Medical University Hospital, Hirakata.
| | - H Sakai
- Department of Thoracic Oncology, Ageo Central General Hospital, Ageo
| | - K Hotta
- Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama
| | - M Takenoyama
- Department of Thoracic Surgery, Matsuyama Red Cross Hospital, Matsuyama
| | - K Yamada
- Department of Respiratory Medicine, Shin Koga Hospital, Fukuoka
| | - S Sugawara
- Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai
| | - Y Takiguchi
- Department of Medical Oncology, Chiba University Hospital, Chiba
| | - Y Hosomi
- Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo
| | - K Tomii
- Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe
| | - S Niho
- Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University, Mibu
| | - M Nishio
- Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo
| | - T Kato
- Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama
| | - T Takahashi
- Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi
| | - H Ebi
- Pharmaceuticals Group, Nippon Kayaku Co., Ltd, Chiyoda-ku, Tokyo
| | - M Aono
- Pharmaceuticals Group, Nippon Kayaku Co., Ltd, Chiyoda-ku, Tokyo
| | - N Yamamoto
- Internal Medicine III, Wakayama Medical University, Wakayama
| | - Y Ohe
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo
| | - K Nakagawa
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan
| |
Collapse
|
4
|
Eaton AG, Weinberger TI, Popiel NJM, Wu Z, Hickey AJ, Cabala A, Pospíšil J, Prokleška J, Haidamak T, Bastien G, Opletal P, Sakai H, Haga Y, Nowell R, Benjamin SM, Sechovský V, Lonzarich GG, Grosche FM, Vališka M. Quasi-2D Fermi surface in the anomalous superconductor UTe 2. Nat Commun 2024; 15:223. [PMID: 38172154 PMCID: PMC10764345 DOI: 10.1038/s41467-023-44110-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2023] [Accepted: 11/30/2023] [Indexed: 01/05/2024] Open
Abstract
The heavy fermion paramagnet UTe2 exhibits numerous characteristics of spin-triplet superconductivity. Efforts to understand the microscopic details of this exotic superconductivity have been impeded by uncertainty regarding the underlying electronic structure. Here we directly probe the Fermi surface of UTe2 by measuring magnetic quantum oscillations in pristine quality crystals. We find an angular profile of quantum oscillatory frequency and amplitude that is characteristic of a quasi-2D Fermi surface, which we find is well described by two cylindrical Fermi sheets of electron- and hole-type respectively. Additionally, we find that both cylindrical Fermi sheets possess considerable undulation but negligible small-scale corrugation, which may allow for their near-nesting and therefore promote magnetic fluctuations that enhance the triplet pairing mechanism. Importantly, we find no evidence for the presence of any 3D Fermi surface sections. Our results place strong constraints on the possible symmetry of the superconducting order parameter in UTe2.
Collapse
Affiliation(s)
- A G Eaton
- Cavendish Laboratory, University of Cambridge, JJ Thomson Avenue, Cambridge, CB3 0HE, UK.
| | - T I Weinberger
- Cavendish Laboratory, University of Cambridge, JJ Thomson Avenue, Cambridge, CB3 0HE, UK
| | - N J M Popiel
- Cavendish Laboratory, University of Cambridge, JJ Thomson Avenue, Cambridge, CB3 0HE, UK
| | - Z Wu
- Cavendish Laboratory, University of Cambridge, JJ Thomson Avenue, Cambridge, CB3 0HE, UK
| | - A J Hickey
- Cavendish Laboratory, University of Cambridge, JJ Thomson Avenue, Cambridge, CB3 0HE, UK
| | - A Cabala
- Charles University, Faculty of Mathematics and Physics, Department of Condensed Matter Physics, Ke Karlovu 5, Prague 2, 121 16, Czech Republic
| | - J Pospíšil
- Charles University, Faculty of Mathematics and Physics, Department of Condensed Matter Physics, Ke Karlovu 5, Prague 2, 121 16, Czech Republic
| | - J Prokleška
- Charles University, Faculty of Mathematics and Physics, Department of Condensed Matter Physics, Ke Karlovu 5, Prague 2, 121 16, Czech Republic
| | - T Haidamak
- Charles University, Faculty of Mathematics and Physics, Department of Condensed Matter Physics, Ke Karlovu 5, Prague 2, 121 16, Czech Republic
| | - G Bastien
- Charles University, Faculty of Mathematics and Physics, Department of Condensed Matter Physics, Ke Karlovu 5, Prague 2, 121 16, Czech Republic
| | - P Opletal
- Advanced Science Research Center, Japan Atomic Energy Agency, Tokai, Ibaraki, 319-1195, Japan
| | - H Sakai
- Advanced Science Research Center, Japan Atomic Energy Agency, Tokai, Ibaraki, 319-1195, Japan
| | - Y Haga
- Advanced Science Research Center, Japan Atomic Energy Agency, Tokai, Ibaraki, 319-1195, Japan
| | - R Nowell
- National High Magnetic Field Laboratory, Tallahassee, FL, 32310, USA
| | - S M Benjamin
- National High Magnetic Field Laboratory, Tallahassee, FL, 32310, USA
| | - V Sechovský
- Charles University, Faculty of Mathematics and Physics, Department of Condensed Matter Physics, Ke Karlovu 5, Prague 2, 121 16, Czech Republic
| | - G G Lonzarich
- Cavendish Laboratory, University of Cambridge, JJ Thomson Avenue, Cambridge, CB3 0HE, UK
| | - F M Grosche
- Cavendish Laboratory, University of Cambridge, JJ Thomson Avenue, Cambridge, CB3 0HE, UK
| | - M Vališka
- Charles University, Faculty of Mathematics and Physics, Department of Condensed Matter Physics, Ke Karlovu 5, Prague 2, 121 16, Czech Republic
| |
Collapse
|
5
|
Tokunaga Y, Sakai H, Kambe S, Opletal P, Tokiwa Y, Haga Y, Kitagawa S, Ishida K, Aoki D, Knebel G, Lapertot G, Krämer S, Horvatić M. Longitudinal Spin Fluctuations Driving Field-Reinforced Superconductivity in UTe_{2}. Phys Rev Lett 2023; 131:226503. [PMID: 38101342 DOI: 10.1103/physrevlett.131.226503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/06/2023] [Revised: 09/29/2023] [Accepted: 10/18/2023] [Indexed: 12/17/2023]
Abstract
Our measurements of ^{125}Te NMR relaxations reveal an enhancement of electronic spin fluctuations above μ_{0}H^{*}∼15 T, leading to their divergence in the vicinity of the metamagnetic transition at μ_{0}H_{m}≈35 T, below which field-reinforced superconductivity appears when a magnetic field (H) is applied along the crystallographic b axis. The NMR data evidence that these fluctuations are dominantly longitudinal, providing a key to understanding the peculiar superconducting phase diagram in H∥b, where such fluctuations enhance the pairing interactions.
Collapse
Affiliation(s)
- Y Tokunaga
- ASRC, Japan Atomic Energy Agency Tokai, Ibaraki 319-1195, Japan
| | - H Sakai
- ASRC, Japan Atomic Energy Agency Tokai, Ibaraki 319-1195, Japan
| | - S Kambe
- ASRC, Japan Atomic Energy Agency Tokai, Ibaraki 319-1195, Japan
| | - P Opletal
- ASRC, Japan Atomic Energy Agency Tokai, Ibaraki 319-1195, Japan
| | - Y Tokiwa
- ASRC, Japan Atomic Energy Agency Tokai, Ibaraki 319-1195, Japan
| | - Y Haga
- ASRC, Japan Atomic Energy Agency Tokai, Ibaraki 319-1195, Japan
| | - S Kitagawa
- Department of Physics, Graduate School of Science, Kyoto University, Kyoto 606-8502, Japan
| | - K Ishida
- Department of Physics, Graduate School of Science, Kyoto University, Kyoto 606-8502, Japan
| | - D Aoki
- IMR, Tohoku University, Ibaraki 311-1313, Japan
- Université Grenoble Alpes, CEA, Grenoble-INP, IRIG, Pheliqs, 38000 Grenoble, France
| | - G Knebel
- Université Grenoble Alpes, CEA, Grenoble-INP, IRIG, Pheliqs, 38000 Grenoble, France
| | - G Lapertot
- Université Grenoble Alpes, CEA, Grenoble-INP, IRIG, Pheliqs, 38000 Grenoble, France
| | - S Krämer
- Laboratoire National des Champs Magnétiques Intenses, LNCMI-CNRS (UPR3228), EMFL, Université Grenoble Alpes, UPS and INSA Toulouse, Boîte Postale 166, 38042 Grenoble Cedex 9, France
| | - M Horvatić
- Laboratoire National des Champs Magnétiques Intenses, LNCMI-CNRS (UPR3228), EMFL, Université Grenoble Alpes, UPS and INSA Toulouse, Boîte Postale 166, 38042 Grenoble Cedex 9, France
| |
Collapse
|
6
|
Baba Y, Nakamaki T, Sakai H, Fukuchi K, Kabasawa N, Hattori N, Harada H. Chronic neutrophilic leukemia preceded by myelodysplastic syndromes. Int J Hematol 2023; 118:636-641. [PMID: 37439996 DOI: 10.1007/s12185-023-03636-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2023] [Revised: 07/03/2023] [Accepted: 07/06/2023] [Indexed: 07/14/2023]
Abstract
Chronic neutrophilic leukemia (CNL) is primarily diagnosed by excluding myelodysplastic syndromes (MDS). We report the case of a patient who developed secondary CNL 3 years after hypoplastic MDS. We used droplet digital polymerase chain reaction mutation detection assay to analyze genomic alterations during the progression from MDS to CNL. At the time of MDS diagnosis, U2AF1 Q157P and SETBP1 D868N were dominant and additional mutation of ASXL1 1934_insG was observed. CSF3R T618I and SETBP1 D868N were increasing at the time of CNL diagnosis. We revealed the accumulation of multiple gene mutations during CNL development from MDS. This suggests that CNL was clonally developed from the founding clone of MDS and CSF3R mutation contributes to the development of CNL in the present case. These findings provide insights into the pathology of CNL.
Collapse
Affiliation(s)
- Yuta Baba
- Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-Ku, Yokohama, Kanagawa, 227-8501, Japan.
- Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
| | - Tsuyoshi Nakamaki
- Division of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Hirotaka Sakai
- Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-Ku, Yokohama, Kanagawa, 227-8501, Japan
| | - Kunihiko Fukuchi
- Graduate School of Health Sciences, Showa University, Tokyo, Japan
| | - Nobuyuki Kabasawa
- Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-Ku, Yokohama, Kanagawa, 227-8501, Japan
| | - Norimichi Hattori
- Division of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Hiroshi Harada
- Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-Ku, Yokohama, Kanagawa, 227-8501, Japan
| |
Collapse
|
7
|
Yoshii T, Sakai H, Kawarabayashi J. Influence of conversion factors on the radioactivity evaluation of clearance objects consisting of several materials. Appl Radiat Isot 2023; 200:110984. [PMID: 37597271 DOI: 10.1016/j.apradiso.2023.110984] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2023] [Revised: 04/18/2023] [Accepted: 08/14/2023] [Indexed: 08/21/2023]
Abstract
Control panel waste generated from nuclear power plants is a new candidate for clearance under Japan's amended regulations. In the radioactivity evaluation, a simplified conversion factor for density and source location conditions has been used, assuming that it applies to unmixed materials such as metals. To investigate its applicability to control panels consisting of metal and organic materials, we examined the application of the conventional conversion factor by simulations of radiation measurements for a point source in a control panel.
Collapse
Affiliation(s)
- Taiki Yoshii
- Nuclear Regulation Authority (NRA), 1-9-9, Roppongi, Minato-ku, Tokyo, 106-8450, Japan; Tokyo City University, 1-28-1, Tamazutsumi, Setagaya-ku, Tokyo, 158-8557, Japan.
| | - Hirotaka Sakai
- Nuclear Regulation Authority (NRA), 1-9-9, Roppongi, Minato-ku, Tokyo, 106-8450, Japan
| | - Jun Kawarabayashi
- Tokyo City University, 1-28-1, Tamazutsumi, Setagaya-ku, Tokyo, 158-8557, Japan
| |
Collapse
|
8
|
Sakai H, Hirosue M, Iwata M, Terasawa T. The effect of introducing a nurse-practitioner-led peripherally inserted central venous catheter placement program on the utilization of central venous access device: A retrospective study in Japan. J Vasc Access 2023:11297298231173160. [PMID: 37341211 DOI: 10.1177/11297298231173160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/22/2023] Open
Abstract
BACKGROUND Nurse-led peripherally inserted central venous catheter (PICC) placement teams are common in western hospitals, but they are still in their infancy in Japan. Although implementing a dedicated program may improve ongoing vascular-access management, the direct hospital-level effects of launching a nurse-led PICC team on specific outcomes have not been formally investigated. OBJECTIVES To evaluate the effect of introducing a nurse practitioner (NP)-led PICC-placement program on subsequent utilization of centrally inserted central catheters (CICCs) and to contrast the quality of PICC placements conducted by physicians and NPs. MATERIALS AND METHODS Patients who underwent central venous access devices (CVADs) between 2014 and 2020 at a university hospital in Japan were evaluated retrospectively using an interrupted time-series analysis on the trend for monthly CVAD utilization and logistic regression and propensity score-based analyses for PICC-related complications. RESULTS Among 6007 CVAD placements, 2230 PICCs were inserted into 1658 patients (725 by physicians and 1505 by NPs). The monthly number of CICC utilization fell from 58 in April 2014 to 38 in March 2020, while PICC placements by the NP PICC team increased from 0 to 104. The implementation of the NP PICC program reduced the immediate rate (by 35.5; 95% confidence interval [CI]: 24.1-46.9; p < 0.001) and post-intervention trend (by 2.3; 95% CI: 1.1-3.5; p < 0.001) of monthly CICC utilization. Overall immediate complication rates were lower in the NP group than the physician group (1.5% vs 5.1%; adjusted odds ratio = 0.31; 95% CI: 0.17-0.59; p < 0.001). The cumulative incidences of central line-associated bloodstream infections were comparable between the NP and physician groups (5.9% vs 7.2%; adjusted hazard ratio = 0.96; 95% CI: 0.53-1.75; p = .90). CONCLUSIONS This NP-led PICC program reduced CICC utilization without affecting the quality of PICC placement or complication rate.
Collapse
Affiliation(s)
- Hirotaka Sakai
- Department of Emergency Medicine and General Internal Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
| | - Miyuki Hirosue
- Department of Emergency Medicine and General Internal Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
| | - Mitsunaga Iwata
- Department of Emergency Medicine and General Internal Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
| | - Teruhiko Terasawa
- Department of Emergency Medicine and General Internal Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
| |
Collapse
|
9
|
Sakai H, Tokiwa Y, Opletal P, Kimata M, Awaji S, Sasaki T, Aoki D, Kambe S, Tokunaga Y, Haga Y. Field Induced Multiple Superconducting Phases in UTe_{2} along Hard Magnetic Axis. Phys Rev Lett 2023; 130:196002. [PMID: 37243663 DOI: 10.1103/physrevlett.130.196002] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/03/2022] [Revised: 12/19/2022] [Accepted: 04/04/2023] [Indexed: 05/29/2023]
Abstract
The superconducting (SC) phase diagram in uranium ditelluride is explored under magnetic fields (H) along the hard magnetic b axis using a high-quality single crystal with T_{c}=2.1 K. Simultaneous electrical resistivity and ac magnetic susceptibility measurements discern low- and high-field SC (LFSC and HFSC, respectively) phases with contrasting field-angular dependence. Crystal quality increases the upper critical field of the LFSC phase, but the H^{*} of ∼15 T, at which the HFSC phase appears, is always the same through the various crystals. A phase boundary signature is also observed inside the LFSC phase near H^{*}, indicating an intermediate SC phase characterized by small flux pinning forces.
Collapse
Affiliation(s)
- H Sakai
- Advanced Science Research Center, Japan Atomic Energy Agency, Tokai, Ibaraki 319-1195, Japan
| | - Y Tokiwa
- Advanced Science Research Center, Japan Atomic Energy Agency, Tokai, Ibaraki 319-1195, Japan
| | - P Opletal
- Advanced Science Research Center, Japan Atomic Energy Agency, Tokai, Ibaraki 319-1195, Japan
| | - M Kimata
- Institute for Materials Research, Tohoku University, Sendai, 980-8577, Japan
| | - S Awaji
- High Field Laboratory for Superconducting Materials, Institute for Materials Research, Tohoku University, Sendai 980-8577, Japan
| | - T Sasaki
- Institute for Materials Research, Tohoku University, Sendai, 980-8577, Japan
| | - D Aoki
- Institute for Materials Research, Tohoku University, Oarai, Ibaraki 311-1313, Japan
| | - S Kambe
- Advanced Science Research Center, Japan Atomic Energy Agency, Tokai, Ibaraki 319-1195, Japan
| | - Y Tokunaga
- Advanced Science Research Center, Japan Atomic Energy Agency, Tokai, Ibaraki 319-1195, Japan
| | - Y Haga
- Advanced Science Research Center, Japan Atomic Energy Agency, Tokai, Ibaraki 319-1195, Japan
| |
Collapse
|
10
|
Griesinger F, Garassino M, Felip E, Sakai H, Le X, Veillon R, Smit E, Raskin J, Thomas M, Ahn MJ, Vlassak S, Bruns R, Johne A, Paik P. 34P Treatment sequencing in the VISION study of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00288-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/03/2023]
|
11
|
Baba Y, Sakai H, Kabasawa N, Harada H. Successful Treatment of an Aggressive Adult T-cell Leukemia/Lymphoma with Strong CD30 Expression Using Brentuximab Vedotin as Combination and Maintenance Therapy. Intern Med 2023; 62:613-616. [PMID: 35871596 PMCID: PMC10017244 DOI: 10.2169/internalmedicine.9812-22] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Adult T-cell leukemia/lymphoma (ATL) is a highly aggressive malignant tumor associated with a poor prognosis. We herein report a 63-year-old man who was newly diagnosed with aggressive ATL. He was treated with brentuximab vedotin (BV) plus cyclophosphamide, doxorubicin, and prednisone (A+CHP therapy), along with intrathecal chemotherapy using methotrexate and cytarabine. After achieving remission, he was placed on maintenance therapy with BV in the outpatient setting every 21 days for 17 months, without relapse. We suggest that initial treatment with A+CHP therapy and BV maintenance therapy may be beneficial against strongly CD30-expressing ATL.
Collapse
Affiliation(s)
- Yuta Baba
- Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Japan
| | - Hirotaka Sakai
- Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Japan
| | - Nobuyuki Kabasawa
- Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Japan
| | - Hiroshi Harada
- Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Japan
| |
Collapse
|
12
|
Yang JH, Kato T, Ahn MJ, Sakai H, Morise M, Chen YM, Han JY, Yang J, Zhao J, Huang JC, Berghoff K, Bruns R, Vioix H, Otto G, Le X, Paik P. 321MO Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: Results from all Asian patients in VISION. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
13
|
Yoshii T, Sakai H, Tagawa H, Kawarabayashi J. Study on the effects of heterogeneity of objects placed in storage containers on simple radioactivity evaluation. ANN NUCL ENERGY 2022. [DOI: 10.1016/j.anucene.2022.109313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
|
14
|
Thomas M, Garassino M, Felip E, Sakai H, Le X, Veillon R, Smit E, Mazieres J, Cortot A, Raskin J, Viteri S, Yang JH, Ahn MJ, Wu YL, Ma R, Zhao J, O'Brate A, Berghoff K, Bruns R, Otto G, Paik P. OA03.05 Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
15
|
Smit E, Garassino M, Felip E, Sakai H, Le X, Veillon R, Mazieres J, Cortot A, Raskin J, Thomas M, Viteri Ramirez S, Berghoff K, Bruns R, Otto G, Paik P. 985P Tepotinib outcomes according to prior therapies in patients with MET exon 14 (METex14) skipping NSCLC. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
16
|
Baba Y, Sakai H, Abe M, Kabasawa N. Extranodal NK/T-cell lymphoma in a unilateral adrenal tumor. Jpn J Clin Oncol 2022; 52:1450-1451. [PMID: 35993112 DOI: 10.1093/jjco/hyac134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Accepted: 07/27/2022] [Indexed: 11/12/2022] Open
Affiliation(s)
- Yuta Baba
- Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Kanagawa, Japan
| | - Hirotaka Sakai
- Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Kanagawa, Japan
| | - Maasa Abe
- Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Kanagawa, Japan
| | - Nobuyuki Kabasawa
- Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Kanagawa, Japan
| |
Collapse
|
17
|
Sakai H, Miura I, Arai A. Quantitative evaluation of treatment response to lenalidomide by applying fluorescence in situ hybridization for peripheral blood granulocytes in a patient with 5q- syndrome. J Clin Exp Hematop 2022; 62:158-163. [PMID: 35732408 PMCID: PMC9635032 DOI: 10.3960/jslrt.22001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
The introduction of lenalidomide has significantly improved clinical outcomes in myelodysplastic syndrome (MDS) with isolated interstitial deletion of the long arm of chromosome 5 (del(5q)) (5q– syndrome). These days, MDS with isolated del(5q) includes cases with one additional chromosome abnormality other than monosomy 7 or del(7q), and so we need a better way to monitor tumor cells in each patient than the clinical parameters used to date. An 82-year-old woman with MDS with isolated del(5q) was treated with lenalidomide daily for 21 days in a 4-week cycle. Fluorescence in situ hybridization with CSF1R located at 5q was applied to the peripheral blood samples. Because mature lymphocytes are not involved in the MDS clone, based on the nuclear morphology, polymorphonuclear cells (PMNs) and round-shaped nuclear cells (RSNs) were separately evaluated during treatment. After a single course of treatment, the number of PMNs with del(5q) decreased; by the end of the second course of treatment, both PMNs and RSNs with del(5q) had disappeared. The dynamics of 5q– PMNs is a simple but rapid and reliable indicator to confirm the effect of lenalidomide in MDS with del(5q).
Collapse
Affiliation(s)
- Hirotaka Sakai
- Division of Hematology, Internal Medicine, Showa University Fujigaoka Hospital, Kanagawa, Japan.,Division of Hematology and Oncology, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan
| | - Ikuo Miura
- Division of Hematology and Oncology, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan.,Center for Genetic and Chromosomal Analysis, SRL, Inc., Tokyo, Japan
| | - Ayako Arai
- Division of Hematology and Oncology, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan
| |
Collapse
|
18
|
Sakai H, Yoshii T, Yunoki A. Evaluation of the probability distribution of radioactivity estimated by inverse problem solution using Monte Carlo Method. Appl Radiat Isot 2022; 187:110338. [PMID: 35752112 DOI: 10.1016/j.apradiso.2022.110338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2021] [Revised: 06/11/2022] [Accepted: 06/15/2022] [Indexed: 11/17/2022]
Abstract
In this study, we derived the posterior probability distribution of the total activity estimated by inverse problem solution. The posterior probability distribution was derived by applying the Monte Carlo approach of the GUM Supplement 1 to the model of evaluation. The decision threshold, the detection limit, and the limits of the coverage interval for the results, all of which are defined in ISO 11929-2 as characteristic limits, were also derived.
Collapse
Affiliation(s)
- Hirotaka Sakai
- Regulatory Standard and Research Department, Secretariat of Nuclear Regulation Authority (S/NRA/R), 1-9-9, Roppongi, Minato-ku, Tokyo, 106-8450, Japan.
| | - Taiki Yoshii
- Regulatory Standard and Research Department, Secretariat of Nuclear Regulation Authority (S/NRA/R), 1-9-9, Roppongi, Minato-ku, Tokyo, 106-8450, Japan
| | - Akira Yunoki
- National Institute of Advanced Industrial Science and Technology, 1-1-1 Umezono, Tsukuba-shi, Ibaraki, 305-8568, Japan
| |
Collapse
|
19
|
Abstract
Several vaccines have been developed for coronavirus disease 2019 - caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - in record time. A few cases of immune thrombocytopenic purpura (ITP) following SARS-CoV-2 vaccination have been reported. We herein report a 90-year-old man who received the Pfizer-BioNTech SARS-CoV-2 vaccine (BNT162b2) and developed severe thrombocytopenia with intracranial hemorrhaging and duodenal bleeding, consistent with vaccine-related ITP. He was successfully treated with intravenous immunoglobulin, prednisolone, and eltrombopag and discharged without cytopenia. Vaccine-related ITP should be suspected in patients presenting with abnormal bleeding or purpura after vaccination.
Collapse
Affiliation(s)
- Yuta Baba
- Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Japan
| | - Hirotaka Sakai
- Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Japan
| | - Nobuyuki Kabasawa
- Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Japan
| | - Hiroshi Harada
- Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Japan
| |
Collapse
|
20
|
Yang JH, Ahn MJ, Sakai H, Morise M, Kato T, Chen YM, Han JY, Yang JJ, Zhao J, Huang J, Berghoff K, Bruns R, Otto G, Le X, Paik P. 25P Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.02.034] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
21
|
Haga Y, Opletal P, Tokiwa Y, Yamamoto E, Tokunaga Y, Kambe S, Sakai H. Effect of uranium deficiency on normal and superconducting properties in unconventional superconductor UTe 2. J Phys Condens Matter 2022; 34:175601. [PMID: 35120343 DOI: 10.1088/1361-648x/ac5201] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/17/2021] [Accepted: 02/04/2022] [Indexed: 06/14/2023]
Abstract
Single crystals of the unconventional superconductor UTe2have been grown in various conditions which result in different superconducting transition temperature as well as normal state properties. Stoichiometry of the samples has been characterized by the single-crystal x-ray crystallography and electron microprobe analyses. Superconducting samples are nearly stoichiometric within an experimental error of about 1%, while non-superconducting sample significantly deviates from the ideal composition. The superconducting UTe2showed that the large density of states was partially gapped in the normal state, while the non-superconducting sample is characterized by the relatively large electronic specific heat as reported previously.
Collapse
Affiliation(s)
- Y Haga
- Advanced Science Research Center, Japan Atomic Energy Agency, Japan
| | - P Opletal
- Advanced Science Research Center, Japan Atomic Energy Agency, Japan
| | - Y Tokiwa
- Advanced Science Research Center, Japan Atomic Energy Agency, Japan
| | - E Yamamoto
- Advanced Science Research Center, Japan Atomic Energy Agency, Japan
| | - Y Tokunaga
- Advanced Science Research Center, Japan Atomic Energy Agency, Japan
| | - S Kambe
- Advanced Science Research Center, Japan Atomic Energy Agency, Japan
| | - H Sakai
- Advanced Science Research Center, Japan Atomic Energy Agency, Japan
| |
Collapse
|
22
|
Paik P, O'Hara R, Veillon R, Felip E, Cortot A, Sakai H, Mazières J, Thomas M, Reinmuth N, Raskin J, Conte P, Garassino M, Iams W, Griesinger F, Kowalski D, Stroh C, Juraeva D, Scheuenpflug J, Johne A, Le X. METex14 ctDNA Dynamics & Resistance Mechanisms Detected in Liquid Biopsy (LBx) From Patients (pts) With METex14 Skipping NSCLC Treated With Tepotinib. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2021.10.185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
23
|
Reck M, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Reyes F, Souquet PJ, De Marchi P, Martin C, Pérol M, Scherpereel A, Lu S, Paz-Ares L, Carbone DP, Memaj A, Marimuthu S, Zhang X, Tran P, John T. Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273]. ESMO Open 2021; 6:100345. [PMID: 34864501 PMCID: PMC8649668 DOI: 10.1016/j.esmoop.2021.100345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Affiliation(s)
- M Reck
- Department of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, LungClinic, Grosshansdorf, Germany.
| | - T-E Ciuleanu
- Department of Oncology, Institutul Oncologic Prof Dr Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania
| | - M Cobo
- Department of Medical Oncology, Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain
| | - M Schenker
- Department of Oncology, SF Nectarie Oncology Center, Craiova, Romania
| | - B Zurawski
- Department of Clinical Oncology, Ambulatorium Chemioterapii, Bydgoszcz, Poland
| | - J Menezes
- Department of Oncology, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil
| | - E Richardet
- Department of Clinical Oncology, Instituto Oncológico de Córdoba, Córdoba, Argentina
| | - J Bennouna
- Department of Thoracic Oncology, University Hospital of Nantes and INSERM, CRCINA, Nantes, France
| | - E Felip
- Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - O Juan-Vidal
- Department of Medical Oncology, Hospital Universitario La Fe, Valencia, Spain
| | - A Alexandru
- Department of Oncology, Institute of Oncology Prof Dr Alexandru Trestioreanu Bucha, Bucharest, Romania
| | - H Sakai
- Department of Thoracic Oncology, Saitama Cancer Center, Saitama, Japan
| | - A Lingua
- Department of Medical Oncology, Instituto Medico Rio Cuarto, SA, Córdoba, Argentina
| | - F Reyes
- Department of Medical Oncology, Fundación Arturo López Pérez, Santiago, Metropolitana, Chile
| | - P-J Souquet
- Department of Pneumology, Hôpital Lyon Sud, Lyon, Pierre Bénite, France
| | - P De Marchi
- Department of Oncology, Barretos Cancer Hospital, Barretos, Brazil
| | - C Martin
- Department of Thoracic Oncology, Instituto Alexander Fleming, Buenos Aires, Argentina
| | - M Pérol
- Department of Thoracic Oncology, Léon Bérard Cancer Center, Lyon, France
| | - A Scherpereel
- Department of Pulmonary and Thoracic Oncology, University of Lille, CHU Lille, INSERM U1189, OncoThAI, Lille, France
| | - S Lu
- Department of Medical Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, China
| | - L Paz-Ares
- Department of Medical Oncology, Hospital Universitario 12 de Octubre, CNIO-H12o Lung Cancer Clinical Research Unit, Universidad Complutense & CiberOnc, Madrid, Spain
| | - D P Carbone
- Department of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, USA
| | - A Memaj
- Bristol Myers Squibb, Princeton, USA
| | | | - X Zhang
- Bristol Myers Squibb, Princeton, USA
| | - P Tran
- Bristol Myers Squibb, Princeton, USA
| | - T John
- Department of Medical Oncology, Austin Hospital, Heidelberg, Australia
| |
Collapse
|
24
|
Yokoi K, Sakakibara Y, Inamoto T, Fujii Y, Sakai H. Dual-Task Training Combining Cognitive Tasks and Occupations among Japanese Community-Dwelling Older Adults: A Pilot Study. Occup Ther Health Care 2021; 36:422-439. [PMID: 34865607 DOI: 10.1080/07380577.2021.2010159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
This study investigated whether dual tasks comprising cognitive tasks and occupations related to daily living can improve the mental and cognitive function of Japanese community-dwelling older adults. Participants included 30 older adults, equally divided into intervention and control groups. The outcome measures were memory, attention, depression, and health-related quality of life. No adverse effects of the intervention were observed in any participant in the intervention group. Logical memory I, logical memory II, and Center for Epidemiologic Studies Depression Scale scores showed a significant interaction. Dual tasks combining cognitive tasks and occupations may help improve delayed recall and alleviate depression. A novel attempt to integrate cognitive stimulation and activities valued by individuals may help mediate age-related cognitive function decline and reduce depressive symptoms in community-dwelling older adults.
Collapse
Affiliation(s)
- K Yokoi
- Occupational Therapy, Graduate School of Comprehensive Rehabilitation, Osaka Prefecture University, Habikino, Japan
| | - Y Sakakibara
- Osaka College of Medical and Welfare, Osaka, Japan
| | - T Inamoto
- Home-Visit Nursing Station Kanaeru Heart, Kawachinagano, Japan
| | - Y Fujii
- Faculty of Health Sciences, Kansai University of Welfare Sciences, Kashiwara, Japan
| | - H Sakai
- Faculty of Health Sciences, Kansai University of Welfare Sciences, Kashiwara, Japan
| |
Collapse
|
25
|
Reck M, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Reyes F, Souquet PJ, De Marchi P, Martin C, Pérol M, Scherpereel A, Lu S, Paz-Ares L, Carbone DP, Memaj A, Marimuthu S, Zhang X, Tran P, John T. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. ESMO Open 2021; 6:100273. [PMID: 34607285 PMCID: PMC8493593 DOI: 10.1016/j.esmoop.2021.100273] [Citation(s) in RCA: 89] [Impact Index Per Article: 29.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Revised: 08/11/2021] [Accepted: 08/23/2021] [Indexed: 11/02/2022] Open
Abstract
BACKGROUND To further characterize survival benefit with first-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone, we report updated data from the phase III CheckMate 9LA trial with a 2-year minimum follow-up. PATIENTS AND METHODS Adult patients were treatment naïve, with stage IV/recurrent non-small-cell lung cancer, no known sensitizing EGFR/ALK alterations, and an Eastern Cooperative Oncology Group performance status ≤1. Patients were randomized 1 : 1 to nivolumab 360 mg every 3 weeks plus ipilimumab 1 mg/kg every 6 weeks with two cycles of chemotherapy, or four cycles of chemotherapy. Updated efficacy and safety outcomes are reported, along with progression-free survival (PFS) after next line of treatment (PFS2), treatment-related adverse events (TRAEs) by treatment cycle, and efficacy outcomes in patients who discontinued all treatment components in the experimental arm due to TRAEs. RESULTS With a median follow-up of 30.7 months, nivolumab plus ipilimumab with chemotherapy continued to prolong overall survival (OS) versus chemotherapy. Median OS was 15.8 versus 11.0 months [hazard ratio 0.72 (95% confidence interval 0.61-0.86)]; 2-year OS rate was 38% versus 26%. Two-year PFS rate was 20% versus 8%. ORR was 38% versus 25%, respectively; 34% versus 12% of all responses were ongoing at 2 years. Median PFS2 was 13.9 versus 8.7 months. Improved efficacy outcomes in the experimental versus control arm were observed across most subgroups, including by programmed death-ligand 1 and histology. No new safety signals were observed; onset of grade 3/4 TRAEs was mostly observed during the first two treatment cycles in the experimental arm. In patients who discontinued all components of nivolumab plus ipilimumab with chemotherapy treatment due to TRAEs (n = 61) median OS was 27.5 months; 56% of responders had an ongoing response ≥1 year after discontinuation. CONCLUSIONS With a 2-year minimum follow-up, nivolumab plus ipilimumab with two cycles of chemotherapy provided durable efficacy benefits over chemotherapy with a manageable safety profile and remains an efficacious first-line treatment of advanced non-small-cell lung cancer.
Collapse
Affiliation(s)
- M Reck
- Department of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, LungClinic, Grosshansdorf, Germany.
| | - T-E Ciuleanu
- Department of Oncology, Institutul Oncologic Prof Dr Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania
| | - M Cobo
- Department of Medical Oncology, Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain
| | - M Schenker
- Department of Oncology, SF Nectarie Oncology Center, Craiova, Romania
| | - B Zurawski
- Department of Clinical Oncology, Ambulatorium Chemioterapii, Bydgoszcz, Poland
| | - J Menezes
- Department of Oncology, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil
| | - E Richardet
- Department of Clinical Oncology, Instituto Oncológico de Córdoba, Córdoba, Argentina
| | - J Bennouna
- Department of Thoracic Oncology, University Hospital of Nantes and INSERM, CRCINA, Nantes, France
| | - E Felip
- Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona
| | - O Juan-Vidal
- Department of Medical Oncology, Hospital Universitario La Fe, Valencia, Spain
| | - A Alexandru
- Department of Oncology, Institute of Oncology Prof Dr Alexandru Trestioreanu Bucha, Bucharest, Romania
| | - H Sakai
- Department of Thoracic Oncology, Saitama Cancer Center, Saitama, Japan
| | - A Lingua
- Department of Medical Oncology, Instituto Medico Rio Cuarto, SA, Córdoba, Argentina
| | - F Reyes
- Department of Medical Oncology, Fundación Arturo López Pérez, Santiago, Metropolitana, Chile
| | - P-J Souquet
- Department of Pneumology, Hôpital Lyon Sud, Lyon, Pierre Bénite, France
| | - P De Marchi
- Department of Oncology, Barretos Cancer Hospital, Barretos, Brazil
| | - C Martin
- Department of Thoracic Oncology, Instituto Alexander Fleming, Buenos Aires, Argentina
| | - M Pérol
- Department of Thoracic Oncology, Léon Bérard Cancer Center, Lyon, France
| | - A Scherpereel
- Department of Pulmonary and Thoracic Oncology, University of Lille, CHU Lille, INSERM U1189, OncoThAI, Lille, France
| | - S Lu
- Department of Medical Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, China
| | - L Paz-Ares
- Department of Medical Oncology, Hospital Universitario 12 de Octubre, CNIO-H12o Lung Cancer Clinical Research Unit, Universidad Complutense & CiberOnc, Madrid, Spain
| | - D P Carbone
- Department of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, USA
| | - A Memaj
- Bristol Myers Squibb, Princeton, USA
| | | | - X Zhang
- Bristol Myers Squibb, Princeton, USA
| | - P Tran
- Bristol Myers Squibb, Princeton, USA
| | - T John
- Department of Medical Oncology, Austin Hospital, Heidelberg, Australia
| |
Collapse
|
26
|
Felip E, Garassino M, Sakai H, Le X, Veillon R, Smit E, Mazieres J, Cortot A, Raskin J, Thomas M, Viteri S, Iams W, Kim H, Yang J, Stroh C, Otto G, Bruns R, Paik P. P45.03 Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC as Identified by Liquid (LBx) or Tissue (TBx) biopsy. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.471] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
27
|
Kabasawa N, Shiozawa E, Murai S, Homma M, Uesugi Y, Matsui T, Nakata A, Shimada S, Sasaki Y, Baba Y, Watanuki M, Arai N, Fujiwara S, Kawaguchi Y, Tsukamoto H, Uto Y, Yanagisawa K, Hattori N, Sakai H, Harada H, Nakamaki T, Takimoto M, Yamochi-Onizuka T. Increased MYC expression without MYC gene translocation in patients with the diffuse large B-cell-lymphoma subtype of iatrogenic immunodeficiency-associated lymphoproliferative disorders. J Clin Exp Hematop 2021; 61:120-125. [PMID: 34511544 PMCID: PMC8519242 DOI: 10.3960/jslrt.20025] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Post-transplant lymphoproliferative disorder (PTLD) and other iatrogenic immunodeficiency-associated lymphoproliferative disorders (OIIA-LPD) are iatrogenic lymphoproliferative disorders (LPD) that develop in association with immunosuppressive treatment in the setting of organ transplantation and autoimmune disease, respectively. Each has a spectrum of pathologies ranging from lymphoid hyperplasia to lymphoma. To clarify the characteristics of the diffuse large B-cell lymphoma (DLBCL) subtype in a cohort of 25 patients with PTLD or OIIA-LPD from our institute, we selected 13 with a histological subtype of DLBCL, including 2 cases of PTLD and 11 of OIIA-LPD. The median patient age at diagnosis was 70 years, with a female predominance. Both PTLD cases developed after kidney transplant. Of the patients with OIIA-LPD, 10 had rheumatoid arthritis, 1 had mixed connective tissue disease, and 8 were treated using methotrexate. Both of the PTLD patients and 6 of the OIIA-LPD patients had extranodal manifestations. All patients except for one were classified as having the non-germinal center B-cell (non-GCB) subtype according to the Hans algorithm. Tissue samples from 8 patients were positive for CD30 and 8 were positive for Epstein–Barr virus (EBV)-encoded small RNA. Seven patients had MYC-positive tissue samples, but none had MYC translocation. Our study suggests that extranodal manifestations and the non-GCB subtype are common, that EBV is associated with the DLBCL subtype of PTLD and OIIA-LPD, and that anti-CD30 therapy is applicable. In addition, our patients with the DLBCL subtype of PTLD and OIIA-LPD exhibited MYC overexpression without MYC translocation, suggesting an alternative mechanism of MYC upregulation.
Collapse
Affiliation(s)
- Nobuyuki Kabasawa
- Department of Pathology, Showa University School of Medicine, Tokyo, Japan.,Division of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Eisuke Shiozawa
- Department of Pathology, Showa University School of Medicine, Tokyo, Japan
| | - So Murai
- Department of Pathology, Showa University School of Medicine, Tokyo, Japan
| | - Mayumi Homma
- Department of Pathology, Showa University School of Medicine, Tokyo, Japan
| | - Yuka Uesugi
- Division of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Tomoharu Matsui
- Division of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Ayaka Nakata
- Division of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Shotaro Shimada
- Division of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Yohei Sasaki
- Division of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Yuta Baba
- Division of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Megumi Watanuki
- Division of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Nana Arai
- Division of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Shun Fujiwara
- Division of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Yukiko Kawaguchi
- Division of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Hiroyuki Tsukamoto
- Division of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Yui Uto
- Division of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Kouji Yanagisawa
- Division of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Norimichi Hattori
- Division of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Hirotaka Sakai
- Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Kanagawa, Japan
| | - Hiroshi Harada
- Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Kanagawa, Japan
| | - Tsuyoshi Nakamaki
- Division of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Masafumi Takimoto
- Department of Pathology, Showa University School of Medicine, Tokyo, Japan
| | | |
Collapse
|
28
|
Felip E, Vallieres E, Zhou C, Wakelee H, Bondarenko I, Sakai H, Saito H, Ursol G, Kawaguchi K, Liu Y, Levchenko E, Kislov N, Reck M, Liersch R, McNally V, Zhu Q, Ding B, Bennett E, Gitlitz B, Altorki N. LBA9 IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.2120] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
29
|
Fujii Y, Iwasaki R, Ikeda S, Chimura S, Goto M, Yoshizaki K, Sakai H, Ito N, Mori T. Gastrointestinal stromal tumour lacking mutations in the KIT and PDGFRA genes in a cat. J Small Anim Pract 2021; 63:239-243. [PMID: 34409605 DOI: 10.1111/jsap.13416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2021] [Revised: 07/05/2021] [Accepted: 08/06/2021] [Indexed: 11/28/2022]
Abstract
Molecular subtyping in gastrointestinal stromal tumours is a useful method for predicting the efficacy of treatment using tyrosine kinase inhibitors in humans. However, owing to the paucity of reports on mutational analyses, the association between genetic mutations and the therapeutic response to tyrosine kinase inhibitors remains unclear in feline gastrointestinal stromal tumours. In this report, we describe the case of a cat with a gastrointestinal stromal tumour which was unresponsive to tyrosine kinase inhibitors. A mutational analysis revealed that the cat lacked mutations in both the KIT and platelet-derived growth factor receptor-alpha (PDGFRA) genes. Our findings are consistent with the fact that KIT/PDGFRA wild-type gastrointestinal stromal tumours are less responsive to tyrosine kinase inhibitors in humans. This signifies the need for further evaluation and possibly individualised treatment for gastrointestinal stromal tumours in cats on the basis of mutational analyses.
Collapse
Affiliation(s)
- Y Fujii
- Joint Graduate School of Veterinary Sciences, Gifu University, Gifu, Gifu, Japan.,Animal Medical Centre, Gifu University, Gifu, Gifu, Japan
| | - R Iwasaki
- Animal Medical Centre, Gifu University, Gifu, Gifu, Japan
| | - S Ikeda
- Chimura Animal Hospital, Iwakura, Aichi, Japan
| | - S Chimura
- Chimura Animal Hospital, Iwakura, Aichi, Japan
| | - M Goto
- Laboratory of Veterinary Pathology, Faculty of Applied Biological Sciences, Gifu University, Gifu, Gifu, Japan
| | - K Yoshizaki
- Laboratory of Veterinary Pathology, Faculty of Applied Biological Sciences, Gifu University, Gifu, Gifu, Japan
| | - H Sakai
- Joint Graduate School of Veterinary Sciences, Gifu University, Gifu, Gifu, Japan.,Laboratory of Veterinary Pathology, Faculty of Applied Biological Sciences, Gifu University, Gifu, Gifu, Japan
| | - N Ito
- Joint Graduate School of Veterinary Sciences, Gifu University, Gifu, Gifu, Japan
| | - T Mori
- Joint Graduate School of Veterinary Sciences, Gifu University, Gifu, Gifu, Japan.,Animal Medical Centre, Gifu University, Gifu, Gifu, Japan
| |
Collapse
|
30
|
Sakai H, Yamashita H, Nakajima S, Takahashi Y, Kaneko H. AB0391 LOW SERUM COMPLEMENT C3 LEVEL AS A RISK FACTOR FOR RELAPSE OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS: A RETROSPECTIVE COHORT STUDY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:The alternative pathway of complement activation has recently been recognized as a key pathogenic event in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Some previous studies have reported that low serum complement C3 level in AAV patients is associated with more severe renal disease, worse renal prognosis, or higher mortality. However, the correlation between low serum C3 level and AAV relapse remains unclear.Objectives:To analyze the clinical characteristics and outcomes of AAV patients with low serum C3 levels at the time of diagnosis.Methods:We conducted a retrospective observational cohort study including 83 consecutive patients diagnosed with AAV in our hospital from January 1999 to December 2020. Serum C3 levels were measured at diagnosis. AAV included microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA); patients with ANCA-negative AAV were excluded. Patients were divided into low- and high-C3 groups (C3 < 100 and ≥ 100 mg/dL, respectively). We compared the clinical characteristics, and relapse-free and overall survival rates, of the two groups, and identified predictors of AAV relapse.Results:Of the 83 patients (MPA, n = 61; GPA, n = 18; EGPA, n = 4), 20 (24%) were in the low-C3 group. We found no significant group difference in sex, body mass index, disease type, ANCA subtype, Birmingham Vasculitis Activity Score (BVAS), or treatment. The low-C3 group patients were older (p=0.01), and had a higher Five Factor Score (FFS) (p=0.01) and a lower remission rate (p=0.02), than the high-C3 group. The generalized Wilcoxon test revealed that the relapse-free survival time was significantly shorter in the low-C3 group (29 months; 95% confidence interval [CI]: 15–49) than in the high-C3 group (82 months; 95% CI: 61–NA; p=0.01) (Figure 1A). The overall survival was also shorter in the low-C3 group (83 months; 95% CI: 8-121) than in the high-C3 group (112 months; 95% CI: 77-NA; p=0.03) (Figure 1B). In the Cox proportional hazards model, a low C3 level (< 100 mg/dL) (hazard ratio [HR], 3.01; 95% CI: 1.29–7.04], p=0.01) and GPA (HR, 3.04; 95% CI: 1.32–7.01; p=0.01) were independent predictors of AAV relapse.Figure 1.Kaplan-Meier estimates of the relapse-free (A) and overall (B) survival rates of AAV patients by baseline serum C3 levels. Eight patients who did not show remission were excluded in the relapse-free survival analysis. Black line: high-C3 group (≥ 100 mg/dL); red line: low-C3 group (< 100 mg/dL).Conclusion:AAV patients with low C3 levels at diagnosis were at higher risk of relapse. Larger prospective studies are required to confirm these findings.Disclosure of Interests:None declared
Collapse
|
31
|
Mitsunari K, Miyata Y, Matsuo T, Ohba K, Mukae Y, Otsubo A, Harada J, Matsuda T, Mochizuki Y, Sakai H. KIBRA plays as tumour suppressor via phosphorylation of LATS-2 in conventional renal cell carcinoma tissues. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)00931-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
32
|
Kondo T, Miyata Y, Matsuda T, Harada J, Mukae Y, Ohtsubo A, Mitsunari K, Matsuo T, Ohba K, Sakai H. Pathological significance and prognostic utility of KIBRA in upper urinary tract urothelial cancer. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)01161-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
33
|
Miyata Y, Matsuo T, Ohba K, Mitsunari K, Keisuke T, Hayashida Y, Tsurusaki T, Watanabe J, Nishimura N, Nishikido M, Sakai H. A randomized clinical trial of intravesical instillation of MMC and combination of MMC and Ara-C in non-muscle invasive bladder cancer. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)01141-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
34
|
Scherz A, Sakai H, Le X, Felip E, Veillon R, Garassino M, Raskin J, Viteri S, Mazieres J, Cortot A, Smit E, Thomas M, Conte P, Gottfried M, Britschgi C, Bruns R, Otto G, Johne A, Paik P. 157P Tepotinib in patients (pts) with MET exon 14 (METex14) skipping NSCLC: Efficacy results from all pts enrolled in VISION cohort A. J Thorac Oncol 2021. [DOI: 10.1016/s1556-0864(21)01999-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
35
|
Saji H, Sakai H, Kimura H, Miyazawa T, Marushima H, Kojima K. P01.18 Adjuvant Chemotherapy With Modified Nab-Paclitaxel and Carboplatin for Completely Resected NSCLC: Survival Analysis of FAST-Nab. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.342] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
36
|
Veillon R, Sakai H, Le X, Felip E, Garassino M, Cortot A, Smit E, Park K, Griesinger F, Britschgi C, Wu Y, Berghoff K, Otto G, Bruns R, Paik P. FP14.09 Tepotinib Safety in MET Exon 14 (METex14) Skipping NSCLC: Updated Results from the VISION Trial. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
37
|
Kori R, Ookawa J, Sakai H, Kimura H, Miyazawa T, Marushima H, Kojima K, Hara M, Saji H. P40.05 Current Status of a Smoking Cessation Supportive Program on Nurses' Interventions: A Single Institutional Experience. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.814] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
38
|
Kato Y, Watanabe Y, Yamane Y, Mizutani H, Kurimoto F, Yamamoto G, Akagi K, Sakai H. P85.03 PD-L1 Expression and Efficacy of Immunotherapy in Japanese Patients with NSCLC Harboring MET Exon 14 Skipping Mutation. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1225] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
39
|
Paik P, Sakai H, Felip E, Veillon R, Garassino M, Raskin J, Viteri S, Mazieres J, Cortot A, Smit E, Thomas M, Cho B, Conte P, Yang J, Morise M, Chen Y, Park K, Gottfried M, Britschgi C, Bruns R, Otto G, Johne A, Le X. MA11.05 Tepotinib in Patients with MET exon 14 (METex14) Skipping Advanced NSCLC: Updated Efficacy Results from VISION Cohort A. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
40
|
Okada T, Kako E, Konomi T, Masuzawa M, Sakai H, Tsuchiya K, Ueki R, Umemori K, Pizzol P, Poudel A, Tajima T. Systematic evaluation of magnetic sensitivities of anisotropic magnetoresistive sensors at liquid helium temperature for superconducting cavities. Rev Sci Instrum 2021; 92:035003. [PMID: 33820008 DOI: 10.1063/5.0038805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/26/2020] [Accepted: 02/28/2021] [Indexed: 06/12/2023]
Abstract
Trapped magnetic flux in bulk superconductors reduces the quality factor Q in superconducting radio-frequency (SRF) cavities. However, the mechanisms underlying flux trapping and radio-frequency loss are not well understood. Detailed observation of the magnetic distributions is important for understanding such phenomena. Magnetic field mapping is useful for observing the magnetic field distribution around SRF cavities. Measuring the change in the magnetic field around the cavity elucidates the flux trapping behavior. Anisotropic magnetoresistive (AMR) sensors are inexpensive and small devices that can detect magnetic flux density. The magnetic sensitivities of AMR sensors need to be evaluated at liquid helium temperature for the magnetic field mapping of SRF cavities. In this study, a test stand was constructed to calibrate the magnetic sensitivities of AMR sensors in liquid helium, and 110 AMR sensors were tested using this stand. The magnetic sensitivities were evaluated systematically. A solenoid coil was used to control the uniform external magnetic field and to measure the magnetic sensitivity at low temperatures. All AMR sensors exhibited suitable sensitivities to the magnetic field around the SRF cavity. The variation in these sensitivities in all AMR sensors was ∼1%. The AMR sensors were found to have sufficient sensitivity for mapping the magnetic field around the exterior surface of the SRF cavity.
Collapse
Affiliation(s)
- T Okada
- SOKENDAI, The Graduate University of Advanced Studies, 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - E Kako
- SOKENDAI, The Graduate University of Advanced Studies, 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - T Konomi
- SOKENDAI, The Graduate University of Advanced Studies, 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - M Masuzawa
- SOKENDAI, The Graduate University of Advanced Studies, 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - H Sakai
- SOKENDAI, The Graduate University of Advanced Studies, 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - K Tsuchiya
- SOKENDAI, The Graduate University of Advanced Studies, 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - R Ueki
- SOKENDAI, The Graduate University of Advanced Studies, 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - K Umemori
- SOKENDAI, The Graduate University of Advanced Studies, 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - P Pizzol
- LANL, Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - A Poudel
- LANL, Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - T Tajima
- LANL, Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| |
Collapse
|
41
|
Sakai H, Yoshii T, Kawasaki S. Derivation of uncertainty propagation for clearance measurement. Appl Radiat Isot 2021; 170:109630. [PMID: 33561750 DOI: 10.1016/j.apradiso.2021.109630] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2020] [Revised: 01/27/2021] [Accepted: 01/28/2021] [Indexed: 11/29/2022]
Abstract
Clearance measurements are performed to calculate the sum of the ratios of the measured activity concentration to the limit for all nuclides to be considered. In the derivation of the uncertainty, the modeling of the measurement is essential. By using formula for the modeling, the uncertainty and upper limits of the coverage interval can be calculated by uncertainty propagation. The treatment of the ratio of the activity concentration of difficult-to-measure-nuclides to that of the key nuclide is also described.
Collapse
Affiliation(s)
- Hirotaka Sakai
- Regulatory Standard and Research Department, Secretariat of Nuclear Regulation Authority (S/NRA/R), 1-9-9, Roppongi, Minato-ku, Tokyo 106-8450, Japan.
| | - Taiki Yoshii
- Regulatory Standard and Research Department, Secretariat of Nuclear Regulation Authority (S/NRA/R), 1-9-9, Roppongi, Minato-ku, Tokyo 106-8450, Japan
| | - Satoru Kawasaki
- Regulatory Standard and Research Department, Secretariat of Nuclear Regulation Authority (S/NRA/R), 1-9-9, Roppongi, Minato-ku, Tokyo 106-8450, Japan
| |
Collapse
|
42
|
Mazieres J, Paik P, Felip E, Veillon R, Sakai H, Cortot A, Viteri S, Garassino M, Van Meerbeeck J, Raskin J, Thomas M, Morise M, Cho B, Conte P, Bruns R, Demuth T, Schumacher K, Le X. OA05.03 Tepotinib in Patients with Advanced NSCLC with MET Exon 14 (METex14) Skipping: Overall Efficacy Results from VISION Cohort A. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2020.10.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
43
|
Maeda A, Murakami M, Iwasaki R, Goto S, Kitagawa K, Sakai H, Mori T. Three-dimensional conformal radiation therapy for canine aortic body tumour: 6 cases (2014-2019). J Small Anim Pract 2020; 62:385-390. [PMID: 33300156 DOI: 10.1111/jsap.13241] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2020] [Revised: 09/15/2020] [Accepted: 09/16/2020] [Indexed: 12/25/2022]
Abstract
OBJECTIVE To determine the feasibility of three-dimensional conformal radiation therapy for canine aortic body tumours. MATERIALS AND METHODS Medical records of dogs that had undergone three-dimensional conformal radiation therapy with presumptive diagnosis of aortic body tumour were reviewed for clinical characteristics, treatment modality and outcomes. RESULTS Eight dogs were diagnosed with aortic body tumour and were treated with three-dimensional conformal radiation therapy. One dog had proliferation of a mass in the right atrium during treatment and died of respiratory distress. Another dog did not undergo follow-up CT to evaluate the treatment response due to the increased blood urea nitrogen values. The remaining 6 dogs were included in the case series. Radiotherapy was performed using a median dose per fraction of 7 Gy (3.3-7.14 Gy), a median of seven divided doses (7-15) and a total median dose of 49 Gy (45-50 Gy). The median number of CT scans during the follow-up period was 5 (range: 3-8 times). CT revealed acute side effects in four dogs-grade 1 effects related to the lung (n = 4) and skin (n = 2). Self-limiting or asymptomatic late side effects (grade 1 lung-related effect) were observed in three dogs. After therapy, one dog demonstrated a complete response, another demonstrated a partial response and the disease remained stable in four animals. The median follow-up period was 514.5 (235-1219) days. After three-dimensional conformal radiation therapy, the aortic body tumour reduced gradually over time without regrowth in all these 6 dogs. CLINICAL SIGNIFICANCE In this small case series, aortic body tumours responded to three-dimensional conformal radiation therapy. Transient and self-limiting side effects of the treatments were common. Further controlled studies are required to prove the effectiveness and the safety of this intervention.
Collapse
Affiliation(s)
- A Maeda
- Department of Veterinary Medicine, Faculty of Applied Biological Sciences, Gifu University, Gifu, Japan
| | - M Murakami
- Laboratory of Veterinary Clinical Oncology, Department of Veterinary Medicine, Gifu University, Gifu5011193, Japan
| | - R Iwasaki
- Animal Medical Center, Gifu University, Gifu5011193, Japan
| | - S Goto
- Animal Medical Center, Gifu University, Gifu5011193, Japan
| | - K Kitagawa
- Department of Small Animal Clinical Science, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, 48824, USA
| | - H Sakai
- Laboratory of Veterinary Pathology, Department of Veterinary Medicine, Gifu University, Gifu, 5011193, Japan
| | - T Mori
- Laboratory of Veterinary Clinical Oncology, Department of Veterinary Medicine, Gifu University, Gifu5011193, Japan.,Center for Highly Advanced Integration of Nano and Life Sciences, Gifu University (G-CHAIN), Gifu, Japan
| |
Collapse
|
44
|
Otagiri H, Yamadav S, Hashidume M, Sakurai A, Morioka M, Kondo E, Sakai H, Kurita H. A clinical investigation of the association between perioperative oral management and prognostic nutritional index in patients with digestive and urinary cancers. Curr Oncol 2020; 27:257-262. [PMID: 33173377 PMCID: PMC7606050 DOI: 10.3747/co.27.5963] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Background The prognostic nutritional index (pni) is a simple metric calculated using serum albumin and the peripheral lymphocyte count. It was reported that a low pni score is significantly associated with major postoperative complications and poor prognosis. The purpose of the present study was to investigate the effects of perioperative oral management (pom) on the perioperative pni profiles of patients with digestive system or urinary cancers. Study Design The medical records of 181 patients with cancer who underwent surgery and for whom a pni could be calculated were retrospectively reviewed. Results The intervention rate with pom was 34.8%. The median preoperative pni score was 48.25 in all patients with a pom intervention [25% to 75% interquartile range (iqr): 44.38-54.13] and 47.25 in those without an intervention (iqr: 42.0-53.5). Compared with patients not receiving pom, those who received pom had significantly higher pni scores from the early postoperative period (p < 0.05). Notably, of patients who could resume oral intake within 3 days after surgery, those who received pom intervention, compared with those who did not, had significantly higher pni scores from the early postoperative period (p < 0.05). Conclusions Perioperative oral management interventions might have positive effects on the postoperative pni scores of patients with cancer.
Collapse
Affiliation(s)
- H Otagiri
- Department of Dentistry and Oral Surgery, Shinshu University School of Medicine, Matsumoto, Japan
| | - S Yamadav
- Department of Dentistry and Oral Surgery, Shinshu University School of Medicine, Matsumoto, Japan
| | - M Hashidume
- Department of Dentistry and Oral Surgery, Shinshu University School of Medicine, Matsumoto, Japan
| | - A Sakurai
- Department of Dentistry and Oral Surgery, Shinshu University School of Medicine, Matsumoto, Japan
| | - M Morioka
- Department of Dentistry and Oral Surgery, Shinshu University School of Medicine, Matsumoto, Japan
| | - E Kondo
- Department of Dentistry and Oral Surgery, Shinshu University School of Medicine, Matsumoto, Japan
| | - H Sakai
- Department of Dentistry and Oral Surgery, Shinshu University School of Medicine, Matsumoto, Japan
| | - H Kurita
- Department of Dentistry and Oral Surgery, Shinshu University School of Medicine, Matsumoto, Japan
| |
Collapse
|
45
|
Michimasa S, Kobayashi M, Kiyokawa Y, Ota S, Yokoyama R, Nishimura D, Ahn DS, Baba H, Berg GPA, Dozono M, Fukuda N, Furuno T, Ideguchi E, Inabe N, Kawabata T, Kawase S, Kisamori K, Kobayashi K, Kubo T, Kubota Y, Lee CS, Matsushita M, Miya H, Mizukami A, Nagakura H, Oikawa H, Sakai H, Shimizu Y, Stolz A, Suzuki H, Takaki M, Takeda H, Takeuchi S, Tokieda H, Uesaka T, Yako K, Yamaguchi Y, Yanagisawa Y, Yoshida K, Shimoura S. Mapping of a New Deformation Region around ^{62}Ti. Phys Rev Lett 2020; 125:122501. [PMID: 33016755 DOI: 10.1103/physrevlett.125.122501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/03/2020] [Revised: 06/12/2020] [Accepted: 07/21/2020] [Indexed: 06/11/2023]
Abstract
We performed the first direct mass measurements of neutron-rich scandium, titanium, and vanadium isotopes around the neutron number 40 at the RIKEN RI Beam Factory using the time-of-flight magnetic-rigidity technique. The atomic mass excesses of ^{58-60}Sc, ^{60-62}Ti, and ^{62-64}V were measured for the first time. The experimental results show that the two-neutron separation energies in the vicinity of ^{62}Ti increase compared to neighboring nuclei. This shows that the masses of Ti isotopes near N=40 are affected by the Jahn-Teller effect. Therefore, a development of Jahn-Teller stabilization appears below the Cr isotopes, and the systematics in Sc, Ti, and V isotopes suggest that ^{62}Ti is located close to the peak of the Jahn-Teller effect.
Collapse
Affiliation(s)
- S Michimasa
- Center for Nuclear Study, The University of Tokyo, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - M Kobayashi
- Center for Nuclear Study, The University of Tokyo, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Y Kiyokawa
- Center for Nuclear Study, The University of Tokyo, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - S Ota
- Center for Nuclear Study, The University of Tokyo, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - R Yokoyama
- Department of Physics and Astronomy, the University of Tennessee, Knoxville, Tennessee 37996, USA
| | - D Nishimura
- Center for Nuclear Study, The University of Tokyo, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Natural Sciences, Tokyo City University, Tamazutsumi 1-28-1, Setagaya-ku, Tokyo 158-8557, Japan
| | - D S Ahn
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - H Baba
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - G P A Berg
- Department of Physics and Joint Institute for Nuclear Astrophysics, University of Notre Dame, Notre Dame, Indiana 46556, USA
| | - M Dozono
- Center for Nuclear Study, The University of Tokyo, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - N Fukuda
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - T Furuno
- Department of Physics, Kyoto University, Kitashirakawa-Oiwake, Sakyo, Kyoto 606-8502, Japan
| | - E Ideguchi
- Research Center for Nuclear Physics, Osaka University, 10-1 Mihogaoka, Ibaraki, Osaka 567-0047, Japan
| | - N Inabe
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - T Kawabata
- Department of Physics, Kyoto University, Kitashirakawa-Oiwake, Sakyo, Kyoto 606-8502, Japan
| | - S Kawase
- Department of Advanced Energy Engineering Science, Kyushu University, 6-1 Kasuga-koen, Kasuga, Fukuoka 816-8580, Japan
| | - K Kisamori
- Center for Nuclear Study, The University of Tokyo, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - K Kobayashi
- Department of Physics, Rikkyo University, Toshima, Tokyo 171-8501, Japan
| | - T Kubo
- Facility for Rare Isotope Beams, Michigan State University, 640 S Shaw Lane, East Lansing, Michigan 48824, USA
- National Superconducting Cyclotron Laboratory, Michigan State University, 640 S Shaw Lane, East Lansing, Michigan 48824, USA
| | - Y Kubota
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - C S Lee
- Center for Nuclear Study, The University of Tokyo, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - M Matsushita
- Center for Nuclear Study, The University of Tokyo, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - H Miya
- Center for Nuclear Study, The University of Tokyo, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - A Mizukami
- Department of Physics, Tokyo University of Science, Noda, Chiba 278-8510, Japan
| | - H Nagakura
- Department of Physics, Rikkyo University, Toshima, Tokyo 171-8501, Japan
| | - H Oikawa
- Department of Physics, Tokyo University of Science, Noda, Chiba 278-8510, Japan
| | - H Sakai
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Y Shimizu
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - A Stolz
- National Superconducting Cyclotron Laboratory, Michigan State University, 640 S Shaw Lane, East Lansing, Michigan 48824, USA
| | - H Suzuki
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - M Takaki
- Center for Nuclear Study, The University of Tokyo, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - H Takeda
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - S Takeuchi
- Department of Physics, Tokyo Institute of Technology, Meguro, Tokyo 152-8551, Japan
| | - H Tokieda
- Center for Nuclear Study, The University of Tokyo, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - T Uesaka
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - K Yako
- Center for Nuclear Study, The University of Tokyo, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Y Yamaguchi
- Center for Nuclear Study, The University of Tokyo, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Y Yanagisawa
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - K Yoshida
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - S Shimoura
- Center for Nuclear Study, The University of Tokyo, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| |
Collapse
|
46
|
Mazieres J, Paik P, Felip E, Veillon R, Sakai H, Cortot A, Viteri S, Garassino M, Van Meerbeeck J, Raskin J, Thomas M, Morise M, Cho B, Conte P, Bruns R, Demuth T, Schumacher K, Le X. 1283P Tepotinib in patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping: Overall efficacy results from VISION cohort A. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1597] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
47
|
Tang TL, Uesaka T, Kawase S, Beaumel D, Dozono M, Fujii T, Fukuda N, Fukunaga T, Galindo-Uribarri A, Hwang SH, Inabe N, Kameda D, Kawahara T, Kim W, Kisamori K, Kobayashi M, Kubo T, Kubota Y, Kusaka K, Lee CS, Maeda Y, Matsubara H, Michimasa S, Miya H, Noro T, Obertelli A, Ogata K, Ota S, Padilla-Rodal E, Sakaguchi S, Sakai H, Sasano M, Shimoura S, Stepanyan SS, Suzuki H, Takaki M, Takeda H, Tokieda H, Wakasa T, Wakui T, Yako K, Yanagisawa Y, Yasuda J, Yokoyama R, Yoshida K, Yoshida K, Zenihiro J. How Different is the Core of ^{25}F from ^{24}O_{g.s.} ? Phys Rev Lett 2020; 124:212502. [PMID: 32530645 DOI: 10.1103/physrevlett.124.212502] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/25/2018] [Revised: 12/15/2019] [Accepted: 04/13/2020] [Indexed: 06/11/2023]
Abstract
The structure of a neutron-rich ^{25}F nucleus is investigated by a quasifree (p,2p) knockout reaction at 270A MeV in inverse kinematics. The sum of spectroscopic factors of π0d_{5/2} orbital is found to be 1.0±0.3. However, the spectroscopic factor with residual ^{24}O nucleus being in the ground state is found to be only 0.36±0.13, while those in the excited state is 0.65±0.25. The result shows that the ^{24}O core of ^{25}F nucleus significantly differs from a free ^{24}O nucleus, and the core consists of ∼35% ^{24}O_{g.s.}. and ∼65% excited ^{24}O. The result may infer that the addition of the 0d_{5/2} proton considerably changes neutron structure in ^{25}F from that in ^{24}O, which could be a possible mechanism responsible for the oxygen dripline anomaly.
Collapse
Affiliation(s)
- T L Tang
- Center for Nuclear Study, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - T Uesaka
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - S Kawase
- Center for Nuclear Study, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - D Beaumel
- Institut de physique nucléaire d'Orsay, 91406 Orsay, France
| | - M Dozono
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - T Fujii
- Center for Nuclear Study, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - N Fukuda
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - T Fukunaga
- Kyushu University, 6-10-1 Hakozaki, Higashi, Fukuoka 812-8581, Japan
| | - A Galindo-Uribarri
- Oak Ridge National Laboratory, 1 Bethel Valley Rd, Oak Ridge, Tennessee 37831, USA
| | - S H Hwang
- Kyungpook National University, 80 Daehakro, Bukgu, Daegu 41566, Republic of Korea
| | - N Inabe
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - D Kameda
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - T Kawahara
- Toho University, 2-2-1 Miyama, Funabashi-shi, Chiba 274-8510, Japan
| | - W Kim
- Kyungpook National University, 80 Daehakro, Bukgu, Daegu 41566, Republic of Korea
| | - K Kisamori
- Center for Nuclear Study, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - M Kobayashi
- Center for Nuclear Study, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - T Kubo
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Y Kubota
- Center for Nuclear Study, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - K Kusaka
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - C S Lee
- Center for Nuclear Study, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - Y Maeda
- University of Miyazaki, 1-1 Gakuen Kibanadai-nishi, Miyazaki 889-2192, Japan
| | - H Matsubara
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - S Michimasa
- Center for Nuclear Study, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - H Miya
- Center for Nuclear Study, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - T Noro
- Kyushu University, 6-10-1 Hakozaki, Higashi, Fukuoka 812-8581, Japan
| | - A Obertelli
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - K Ogata
- RCNP, Osaka University, 10-1 Mihogaoka, Ibaraki, Osaka 567-0047, Japan
- Department of Physics, Osaka City University, Osaka 558-8585, Japan
| | - S Ota
- Center for Nuclear Study, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - E Padilla-Rodal
- Universidad Nacional Autónoma de México, Instituto de Ciencias Nucleares, AP 70-543, México City 04510, DF, México
| | - S Sakaguchi
- Kyushu University, 6-10-1 Hakozaki, Higashi, Fukuoka 812-8581, Japan
| | - H Sakai
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - M Sasano
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - S Shimoura
- Center for Nuclear Study, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - S S Stepanyan
- Kyungpook National University, 80 Daehakro, Bukgu, Daegu 41566, Republic of Korea
| | - H Suzuki
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - M Takaki
- Center for Nuclear Study, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - H Takeda
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - H Tokieda
- Center for Nuclear Study, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - T Wakasa
- Kyushu University, 6-10-1 Hakozaki, Higashi, Fukuoka 812-8581, Japan
| | - T Wakui
- CYRIC, Tohoku University, 6-3 Aoba, Aramaki, Aoba-ku, Sendai, Miyagi 980-8578, Japan
| | - K Yako
- Center for Nuclear Study, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - Y Yanagisawa
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - J Yasuda
- Kyushu University, 6-10-1 Hakozaki, Higashi, Fukuoka 812-8581, Japan
| | - R Yokoyama
- Center for Nuclear Study, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - K Yoshida
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - K Yoshida
- RCNP, Osaka University, 10-1 Mihogaoka, Ibaraki, Osaka 567-0047, Japan
| | - J Zenihiro
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| |
Collapse
|
48
|
Mitsuishi N, Sugita Y, Bahramy MS, Kamitani M, Sonobe T, Sakano M, Shimojima T, Takahashi H, Sakai H, Horiba K, Kumigashira H, Taguchi K, Miyamoto K, Okuda T, Ishiwata S, Motome Y, Ishizaka K. Switching of band inversion and topological surface states by charge density wave. Nat Commun 2020; 11:2466. [PMID: 32424170 PMCID: PMC7235022 DOI: 10.1038/s41467-020-16290-w] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2019] [Accepted: 04/25/2020] [Indexed: 11/10/2022] Open
Abstract
Topologically nontrivial materials host protected edge states associated with the bulk band inversion through the bulk-edge correspondence. Manipulating such edge states is highly desired for developing new functions and devices practically using their dissipation-less nature and spin-momentum locking. Here we introduce a transition-metal dichalcogenide VTe2, that hosts a charge density wave (CDW) coupled with the band inversion involving V3d and Te5p orbitals. Spin- and angle-resolved photoemission spectroscopy with first-principles calculations reveal the huge anisotropic modification of the bulk electronic structure by the CDW formation, accompanying the selective disappearance of Dirac-type spin-polarized topological surface states that exist in the normal state. Thorough three dimensional investigation of bulk states indicates that the corresponding band inversion at the Brillouin zone boundary dissolves upon the CDW formation, by transforming into anomalous flat bands. Our finding provides a new insight to the topological manipulation of matters by utilizing CDWs' flexible characters to external stimuli.
Collapse
Affiliation(s)
- N Mitsuishi
- Department of Applied Physics, The University of Tokyo, Tokyo, 113-8656, Japan
- Quantum-Phase Electronics Center (QPEC), The University of Tokyo, Wako, 113-8656, Japan
| | - Y Sugita
- Department of Applied Physics, The University of Tokyo, Tokyo, 113-8656, Japan
| | - M S Bahramy
- Department of Applied Physics, The University of Tokyo, Tokyo, 113-8656, Japan
- Quantum-Phase Electronics Center (QPEC), The University of Tokyo, Wako, 113-8656, Japan
- RIKEN Center for Emergent Matter Science (CEMS), Wako, 351-0198, Japan
| | - M Kamitani
- Department of Applied Physics, The University of Tokyo, Tokyo, 113-8656, Japan
- Quantum-Phase Electronics Center (QPEC), The University of Tokyo, Wako, 113-8656, Japan
| | - T Sonobe
- Department of Applied Physics, The University of Tokyo, Tokyo, 113-8656, Japan
- Quantum-Phase Electronics Center (QPEC), The University of Tokyo, Wako, 113-8656, Japan
| | - M Sakano
- Department of Applied Physics, The University of Tokyo, Tokyo, 113-8656, Japan
- Quantum-Phase Electronics Center (QPEC), The University of Tokyo, Wako, 113-8656, Japan
| | - T Shimojima
- RIKEN Center for Emergent Matter Science (CEMS), Wako, 351-0198, Japan
| | - H Takahashi
- Division of Materials Physics, Graduate School of Engineering Science, Osaka University, Toyonaka, Osaka, 560-8531, Japan
| | - H Sakai
- Department of Physics, Osaka University, Toyonaka, Osaka, 560-0043, Japan
| | - K Horiba
- Condensed Matter Research Center and Photon Factory, Institute of Materials Structure Science, High Energy Accelerator Research Organization (KEK), Tsukuba, 305-0801, Japan
| | - H Kumigashira
- Condensed Matter Research Center and Photon Factory, Institute of Materials Structure Science, High Energy Accelerator Research Organization (KEK), Tsukuba, 305-0801, Japan
| | - K Taguchi
- Hiroshima Synchrotron Radiation Center (HSRC), Hiroshima University, 2-313 Kagamiyama, Higashi-Hiroshima, 739-0046, Japan
| | - K Miyamoto
- Hiroshima Synchrotron Radiation Center (HSRC), Hiroshima University, 2-313 Kagamiyama, Higashi-Hiroshima, 739-0046, Japan
| | - T Okuda
- Hiroshima Synchrotron Radiation Center (HSRC), Hiroshima University, 2-313 Kagamiyama, Higashi-Hiroshima, 739-0046, Japan
| | - S Ishiwata
- Division of Materials Physics, Graduate School of Engineering Science, Osaka University, Toyonaka, Osaka, 560-8531, Japan
| | - Y Motome
- Department of Applied Physics, The University of Tokyo, Tokyo, 113-8656, Japan
| | - K Ishizaka
- Department of Applied Physics, The University of Tokyo, Tokyo, 113-8656, Japan.
- Quantum-Phase Electronics Center (QPEC), The University of Tokyo, Wako, 113-8656, Japan.
- RIKEN Center for Emergent Matter Science (CEMS), Wako, 351-0198, Japan.
| |
Collapse
|
49
|
Tanaka N, Shenton M, Kawahara Y, Kumagai M, Sakai H, Kanamori H, Yonemaru J, Fukuoka S, Sugimoto K, Ishimoto M, Wu J, Ebana K. Whole-Genome Sequencing of the NARO World Rice Core Collection (WRC) as the Basis for Diversity and Association Studies. Plant Cell Physiol 2020; 61:922-932. [PMID: 32101292 PMCID: PMC7426033 DOI: 10.1093/pcp/pcaa019] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/31/2019] [Accepted: 02/16/2020] [Indexed: 05/12/2023]
Abstract
Genebanks provide access to diverse materials for crop improvement. To utilize and evaluate them effectively, core collections, such as the World Rice Core Collection (WRC) in the Genebank at the National Agriculture and Food Research Organization, have been developed. Because the WRC consists of 69 accessions with a high degree of genetic diversity, it has been used for >300 projects. To allow deeper investigation of existing WRC data and to further promote research using Genebank rice accessions, we performed whole-genome resequencing of these 69 accessions, examining their sequence variation by mapping against the Oryza sativa ssp. japonica Nipponbare genome. We obtained a total of 2,805,329 single nucleotide polymorphisms (SNPs) and 357,639 insertion-deletions. Based on the principal component analysis and population structure analysis of these data, the WRC can be classified into three major groups. We applied TASUKE, a multiple genome browser to visualize the different WRC genome sequences, and classified haplotype groups of genes affecting seed characteristics and heading date. TASUKE thus provides access to WRC genotypes as a tool for reverse genetics. We examined the suitability of the compact WRC population for genome-wide association studies (GWASs). Heading date, affected by a large number of quantitative trait loci (QTLs), was not associated with known genes, but several seed-related phenotypes were associated with known genes. Thus, for QTLs of strong effect, the compact WRC performed well in GWAS. This information enables us to understand genetic diversity in 37,000 rice accessions maintained in the Genebank and to find genes associated with different phenotypes. The sequence data have been deposited in DNA Data Bank of Japan Sequence Read Archive (DRA) (Supplementary Table S1).
Collapse
Affiliation(s)
- N Tanaka
- Institute of Crop Science, National Agriculture and Food Research Organization, Tsukuba, Ibaraki, 305-8518 Japan
| | - M Shenton
- Institute of Crop Science, National Agriculture and Food Research Organization, Tsukuba, Ibaraki, 305-8518 Japan
| | - Y Kawahara
- Institute of Crop Science, National Agriculture and Food Research Organization, Tsukuba, Ibaraki, 305-8518 Japan
- Advanced Analysis Center, National Agriculture and Food Research Organization, Tsukuba Ibaraki, 305-8517, Japan
| | - M Kumagai
- Advanced Analysis Center, National Agriculture and Food Research Organization, Tsukuba Ibaraki, 305-8517, Japan
| | - H Sakai
- Advanced Analysis Center, National Agriculture and Food Research Organization, Tsukuba Ibaraki, 305-8517, Japan
| | - H Kanamori
- Institute of Crop Science, National Agriculture and Food Research Organization, Tsukuba, Ibaraki, 305-8518 Japan
| | - J Yonemaru
- Institute of Crop Science, National Agriculture and Food Research Organization, Tsukuba, Ibaraki, 305-8518 Japan
| | - S Fukuoka
- Institute of Crop Science, National Agriculture and Food Research Organization, Tsukuba, Ibaraki, 305-8518 Japan
| | - K Sugimoto
- Institute of Crop Science, National Agriculture and Food Research Organization, Tsukuba, Ibaraki, 305-8518 Japan
| | - M Ishimoto
- Institute of Crop Science, National Agriculture and Food Research Organization, Tsukuba, Ibaraki, 305-8518 Japan
| | - J Wu
- Institute of Crop Science, National Agriculture and Food Research Organization, Tsukuba, Ibaraki, 305-8518 Japan
| | - K Ebana
- Genetic Resources Center, National Agriculture and Food Research Organization, Plant Genetic Diversity Laboratory, Tsukuba, Ibaraki 305-8502, Japan
- Corresponding author: E-mail, ; Fax, +81-29-838-7408
| |
Collapse
|
50
|
Saiki Y, Sakai H, Uchida A, Uemura Y, Matsunawa M, Isobe Y, Kato M, Tomita N, Miura I, Arai A. [Leukemic cell kinetics of APL with a novel complex variant t (12;17;15)(p13;q21;q22)]. Rinsho Ketsueki 2020; 61:103-109. [PMID: 32147608 DOI: 10.11406/rinketsu.61.103] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
A 69-year-old woman with leukocytopenia and thrombocytopenia was referred to our hospital. Her bone marrow comprised 70.5% abnormal promyelocytes that were positive for myeloperoxidase/CD33/CD117 and CD13 (dim) and negative for CD2/CD34/CD56 and HLA-DR. Chromosome analysis of the bone marrow showed t (12;17;15) (p13;q21;q22), and fluorescence in situ hybridization revealed the PML-RARA fusion signal only on the derivative chromosome 15. The patient was diagnosed with acute promyelocytic leukemia (APL) with PML-RARA and was treated using all-trans retinoic acid (ATRA). In peripheral blood (PB), PML-RARA-positive polymorphonuclear cells (PMNs) appeared on the second week and became negative on the sixth week after treatment, whereas PML-RARA-negative PMNs started to increase in number on the sixth week. Molecular remission was confirmed on the 10th week. Quantitative evaluation of the differentiated leukemic cells of APL and recovered cells from normal hematopoiesis in PB can provide useful information for a safer induction therapy. No significant difference was noted in the kinetics of the leukemic cells under ATRA treatment as well as in the clinical features between our patient without RARA-PML and those with t (15;17), which is a cytogenetic evidence for the critical role of PML-RARA in the pathogenesis of APL.
Collapse
Affiliation(s)
- Yusuke Saiki
- Department of Internal Medicine, Division of Hematology and Oncology, St. Marianna University School of Medicine
| | - Hirotaka Sakai
- Department of Internal Medicine, Division of Hematology and Oncology, St. Marianna University School of Medicine
| | - Akiko Uchida
- Department of Internal Medicine, Division of Hematology and Oncology, St. Marianna University School of Medicine
| | - Yu Uemura
- Department of Internal Medicine, Division of Hematology and Oncology, St. Marianna University School of Medicine
| | - Manabu Matsunawa
- Department of Internal Medicine, Division of Hematology and Oncology, St. Marianna University School of Medicine
| | - Yasushi Isobe
- Department of Internal Medicine, Division of Hematology and Oncology, St. Marianna University School of Medicine
| | - Masayuki Kato
- Department of Internal Medicine, Division of Hematology and Oncology, St. Marianna University School of Medicine
| | - Naoto Tomita
- Department of Internal Medicine, Division of Hematology and Oncology, St. Marianna University School of Medicine
| | - Ikuo Miura
- Center for Genetic and Chromosomal Analysis, SRL, Inc
| | - Ayako Arai
- Department of Internal Medicine, Division of Hematology and Oncology, St. Marianna University School of Medicine
| |
Collapse
|